TWI725990B - 反義核酸 - Google Patents

反義核酸 Download PDF

Info

Publication number
TWI725990B
TWI725990B TW105130156A TW105130156A TWI725990B TW I725990 B TWI725990 B TW I725990B TW 105130156 A TW105130156 A TW 105130156A TW 105130156 A TW105130156 A TW 105130156A TW I725990 B TWI725990 B TW I725990B
Authority
TW
Taiwan
Prior art keywords
nucleic acid
dna
labor
oligomer
antisense oligomer
Prior art date
Application number
TW105130156A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718858A (zh
Inventor
塩谷由輝子
戸根悠一郎
武田伸一
青木吉嗣
Original Assignee
日商日本新藥股份有限公司
國立研究開發法人國立精神 神經醫療研究中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商日本新藥股份有限公司, 國立研究開發法人國立精神 神經醫療研究中心 filed Critical 日商日本新藥股份有限公司
Publication of TW201718858A publication Critical patent/TW201718858A/zh
Application granted granted Critical
Publication of TWI725990B publication Critical patent/TWI725990B/zh

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/313Phosphorodithioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW105130156A 2015-09-15 2016-09-19 反義核酸 TWI725990B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015182145 2015-09-15
JP2015-182145 2015-09-15

Publications (2)

Publication Number Publication Date
TW201718858A TW201718858A (zh) 2017-06-01
TWI725990B true TWI725990B (zh) 2021-05-01

Family

ID=58289325

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105130156A TWI725990B (zh) 2015-09-15 2016-09-19 反義核酸

Country Status (29)

Country Link
US (4) US10144931B2 (cg-RX-API-DMAC7.html)
EP (2) EP3351633B1 (cg-RX-API-DMAC7.html)
JP (4) JP6384845B2 (cg-RX-API-DMAC7.html)
KR (3) KR102473431B1 (cg-RX-API-DMAC7.html)
CN (3) CN108026531B (cg-RX-API-DMAC7.html)
AU (1) AU2016324800B2 (cg-RX-API-DMAC7.html)
CA (1) CA2996280C (cg-RX-API-DMAC7.html)
CO (1) CO2018002557A2 (cg-RX-API-DMAC7.html)
CY (1) CY1123119T1 (cg-RX-API-DMAC7.html)
DK (1) DK3351633T3 (cg-RX-API-DMAC7.html)
ES (1) ES2808049T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201125T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050061T2 (cg-RX-API-DMAC7.html)
IL (1) IL258065B (cg-RX-API-DMAC7.html)
LT (1) LT3351633T (cg-RX-API-DMAC7.html)
MX (1) MX391304B (cg-RX-API-DMAC7.html)
MY (1) MY185390A (cg-RX-API-DMAC7.html)
PH (1) PH12018500568B1 (cg-RX-API-DMAC7.html)
PL (1) PL3351633T3 (cg-RX-API-DMAC7.html)
PT (1) PT3351633T (cg-RX-API-DMAC7.html)
RS (1) RS60493B1 (cg-RX-API-DMAC7.html)
RU (1) RU2724554C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201802138TA (cg-RX-API-DMAC7.html)
SI (1) SI3351633T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000379T1 (cg-RX-API-DMAC7.html)
TW (1) TWI725990B (cg-RX-API-DMAC7.html)
UA (1) UA123359C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017047707A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801682B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102473431B1 (ko) * 2015-09-15 2022-12-01 니뽄 신야쿠 가부시키가이샤 안티센스 핵산
CN114533900A (zh) 2015-10-09 2022-05-27 波涛生命科学有限公司 寡核苷酸组合物及其方法
EA202190416A1 (ru) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
GB201821269D0 (en) * 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
AU2020263487A1 (en) 2019-04-25 2021-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
WO2022232478A1 (en) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
CA3224782A1 (en) * 2021-06-23 2022-12-29 Nippon Shinyaku Co., Ltd. Combination of antisense oligomers
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
WO2023127918A1 (ja) 2021-12-27 2023-07-06 日本新薬株式会社 オリゴ核酸化合物の製造方法
EP4486386A1 (en) 2022-03-03 2025-01-08 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
US20250195667A1 (en) 2022-03-17 2025-06-19 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201336859A (zh) * 2011-12-28 2013-09-16 Nippon Shinyaku Co Ltd 反意義核酸

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567664A (en) 1948-04-22 1951-09-11 Willis G Ewell Chicken culling device
DE69033986T2 (de) 1989-12-20 2003-03-13 Antivirals Inc., Portland Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体,デバイス及び医薬組成物
JP2000325085A (ja) * 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
US6727355B2 (en) * 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
EP2386636B1 (en) 2002-11-25 2016-01-27 Masafumi Matsuo Ena nucleic acid drugs modifying splicing in mrna precursor
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP1811024A1 (en) 2004-10-05 2007-07-25 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna and medicinal composition
CA2609032A1 (en) 2005-05-30 2006-12-07 Nippon Shinyaku Co., Ltd. Method for producing a nucleic-acid-containing complex preparation
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
US8466255B2 (en) 2007-02-05 2013-06-18 Nippon Shinyaku Co., Ltd. Polyethylene glycol derivative
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
ES2639852T3 (es) * 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
EP2207779B1 (en) 2007-11-15 2014-04-09 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
EP2762567B1 (en) 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
PT2344637E (pt) * 2008-10-27 2015-03-23 Academisch Ziekenhuis Leiden Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
WO2010123369A1 (en) * 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
ITTO20090487A1 (it) * 2009-06-26 2010-12-27 Univ Ferrara Oligonucleotidi antisenso atti ad indurre lo skipping esonico e loro impiego come medicamento per il trattamento della distrofia muscolare di duchenne (dmd)
US20120270930A1 (en) * 2009-10-29 2012-10-25 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods and compositions for dysferlin exon-skipping
PL2499249T3 (pl) 2009-11-12 2019-03-29 Univ Western Australia Cząsteczki antysensowne i sposoby leczenia patologii
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
KR20140052963A (ko) * 2011-02-08 2014-05-07 더 샬롯테-맥클렌버그 하스피털 오쏘러티 디/비/에이 카롤리나스 헬스케어 시스템 안티센스 올리고뉴클레오티드
CN118581086A (zh) * 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
CA2877644A1 (en) * 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
BR112015022998A2 (pt) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
RS58573B1 (sr) 2014-03-12 2019-05-31 Nippon Shinyaku Co Ltd Antisensna nukleinska kiselina
JP2015182145A (ja) 2014-03-20 2015-10-22 キヤノン株式会社 ロボットシステムの制御方法、およびロボットシステム
TWI666317B (zh) 2014-06-17 2019-07-21 Nippon Shinyaku Co., Ltd. 反義核酸
KR102473431B1 (ko) * 2015-09-15 2022-12-01 니뽄 신야쿠 가부시키가이샤 안티센스 핵산

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201336859A (zh) * 2011-12-28 2013-09-16 Nippon Shinyaku Co Ltd 反意義核酸

Also Published As

Publication number Publication date
ES2808049T3 (es) 2021-02-25
CN113913426B (zh) 2024-08-02
CA2996280C (en) 2024-05-07
IL258065A (en) 2018-05-31
KR102473431B1 (ko) 2022-12-01
JP6977998B2 (ja) 2021-12-08
AU2016324800A1 (en) 2018-04-05
SMT202000379T1 (it) 2020-09-10
PH12018500568B1 (en) 2022-09-14
US10851373B2 (en) 2020-12-01
MX391304B (es) 2025-03-21
KR20190040098A (ko) 2019-04-16
PL3351633T3 (pl) 2020-11-02
KR20220053048A (ko) 2022-04-28
HUE050061T2 (hu) 2020-12-28
NZ740562A (en) 2021-11-26
CO2018002557A2 (es) 2018-05-31
JP2018183178A (ja) 2018-11-22
KR20180043244A (ko) 2018-04-27
JPWO2017047707A1 (ja) 2018-07-05
EP3778895A1 (en) 2021-02-17
MY185390A (en) 2021-05-17
JP2022033738A (ja) 2022-03-02
RU2724554C2 (ru) 2020-06-23
US10144931B2 (en) 2018-12-04
CN108026531B (zh) 2021-09-14
IL258065B (en) 2022-02-01
WO2017047707A1 (ja) 2017-03-23
CN113930426A (zh) 2022-01-14
PT3351633T (pt) 2020-07-29
JP6384845B2 (ja) 2018-09-05
LT3351633T (lt) 2020-08-10
JP2024038104A (ja) 2024-03-19
KR101968880B1 (ko) 2019-04-12
CA2996280A1 (en) 2017-03-23
RS60493B1 (sr) 2020-08-31
US11981894B2 (en) 2024-05-14
EP3351633A4 (en) 2019-09-04
US20240368597A1 (en) 2024-11-07
US20180265866A1 (en) 2018-09-20
TW201718858A (zh) 2017-06-01
RU2018113276A (ru) 2019-10-16
PH12018500568A1 (en) 2018-09-24
EP3351633B1 (en) 2020-06-24
AU2016324800B2 (en) 2022-02-24
DK3351633T3 (da) 2020-08-03
HRP20201125T1 (hr) 2020-10-30
US20190040387A1 (en) 2019-02-07
US20210147839A1 (en) 2021-05-20
UA123359C2 (uk) 2021-03-24
CY1123119T1 (el) 2021-10-29
RU2018113276A3 (cg-RX-API-DMAC7.html) 2020-02-06
CN113913426A (zh) 2022-01-11
ZA201801682B (en) 2020-07-29
EP3351633A1 (en) 2018-07-25
SI3351633T1 (sl) 2020-09-30
MX2018002955A (es) 2018-05-02
BR112018004970A2 (pt) 2018-10-09
SG11201802138TA (en) 2018-04-27
CN108026531A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
TWI725990B (zh) 反義核酸
TWI721461B (zh) 反義核酸
CN106459955B (zh) 反义核酸
JP5363655B2 (ja) アンチセンス核酸
JP7201192B2 (ja) エクソン50のスキッピングを誘導するアンチセンス核酸
TWI726914B (zh) 肌萎縮症治療用反義核酸
TWI901457B (zh) 誘導外顯子51跳讀的反義核酸